Company

Hinova Licenses Oral VAV1 Molecular Glue Degrader HP570 to Evommune in Up to USD 1.1 Billion Deal – Days After FDA IND Clearance for Rheumatoid Arthritis
Auto-immuneClinical trial approval / initiation

Hinova Licenses Oral VAV1 Molecular Glue Degrader HP570 to Evommune in Up to USD 1.1 Billion Deal – Days After FDA IND Clearance for Rheumatoid Arthritis

Hinova Pharmaceuticals Inc. (SHA: 688302) announced that its self‑developed investigational drug HP570 received formal Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for the treatment…

Merck Launches Phase 3 ENHANCE‑3 Trial of OHTUVAYRE (Ensifentrine) – Targeting COPD Exacerbation Prevention

Merck Launches Phase 3 ENHANCE‑3 Trial of OHTUVAYRE (Ensifentrine) – Targeting COPD Exacerbation Prevention

Novo Nordisk Raises Full‑Year Guidance on Oral Wegovy Momentum – Q3 Revenue Grows 6% as China Sales Weaken

Novo Nordisk Raises Full‑Year Guidance on Oral Wegovy Momentum – Q3 Revenue Grows 6% as China Sales Weaken

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Sinocelltech Wins NMPA Clearance for TriAb SCTB39G in Solid Tumors
Clinical trial approval / initiationMulti-specific antibodies

Sinocelltech Wins NMPA Clearance for TriAb SCTB39G in Solid Tumors

CARsgen's Satri-cel NDA Accepted by China's NMPA for Gastric Adenocarcinoma
CancerCARsgen Therapeutics

CARsgen’s Satri-cel NDA Accepted by China’s NMPA for Gastric Adenocarcinoma

Lepu Biotech Gains EMA Approval for MRG003 HNSCC Clinical Trial
ADC / XDCClinical trial approval / initiation

Lepu Biopharma Gains EMA Approval for MRG003 HNSCC Clinical Trial

RemeGen Inks Global Licensing Pact With Vor Bio for Telitacicept
HKG: 9995Rare / orphan disease drugs

RemeGen Inks Global Licensing Pact With Vor Biopharma for Telitacicept

Show More